Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PATENT-1
  • Sponsors Bayer
  • Most Recent Events

    • 11 Nov 2017 Results of post hoc analysis from PATENT-1 and PATENT-2 published in the Journal of Heart and Lung Transplantation.
    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2017 According to a Bayer media release, data from this trial will be presented at the 11th annual World Congress of the Pulmonary Vascular Research Institute (PVRI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top